Effectiveness and safety of the simulation-based first-dose design of voriconazole

[1]  Y. Hamada,et al.  Development of a therapeutic drug‐monitoring algorithm for outpatients receiving voriconazole: A multicentre retrospective study , 2024, British journal of clinical pharmacology.

[2]  N. Ohmagari,et al.  Necessity for a System Implementing Therapeutic Drug Monitoring in Outpatient Settings Based on the Actual Use of Voriconazole Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan: A Descriptive Epidemiological Study. , 2023, Biological & pharmaceutical bulletin.

[3]  Y. Hamada,et al.  Optimal timing for therapeutic drug monitoring of voriconazole to prevent adverse effects in Japanese patients , 2023, Mycoses.

[4]  Y. Hamada,et al.  Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. , 2022, Clinical therapeutics.

[5]  X. Su,et al.  Therapeutic drug monitoring and safety evaluation of voriconazole in the treatment of pulmonary fungal diseases , 2022, Therapeutic advances in drug safety.

[6]  F. Stanke-Labesque,et al.  Combined Impact of Inflammation and Pharmacogenomic Variants on Voriconazole Trough Concentrations: A Meta-Analysis of Individual Data , 2021, Journal of clinical medicine.

[7]  Y. Tanigawara,et al.  Population Pharmacokinetics of Voriconazole in Patients with Invasive Aspergillosis: Serum Albumin Level as a Novel Marker for Clearance and Dosage Optimization. , 2020, Therapeutic drug monitoring.

[8]  H. Ikeuchi,et al.  Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan , 2020, Mycoses.

[9]  R. Day,et al.  Voriconazole: an audit of hospital-based dosing and monitoring and evaluation of the predictive performance of a dose-prediction software package. , 2020, The Journal of antimicrobial chemotherapy.

[10]  M. Pirmohamed,et al.  Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study , 2019, Antimicrobial Agents and Chemotherapy.

[11]  L. Xue,et al.  Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study. , 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[12]  S. Zhai,et al.  Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis , 2016, European Journal of Clinical Pharmacology.

[13]  Y. Hamada,et al.  [Evaluation of voriconazole oral dosage in Japan]. , 2014, The Japanese journal of antibiotics.

[14]  P. G. Choe,et al.  The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  Y. Hamada,et al.  Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis , 2012, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[16]  J. Perfect,et al.  Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  N. Wood,et al.  Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. , 2003, British journal of clinical pharmacology.

[18]  D A Smith,et al.  Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[19]  N. Wood,et al.  Pharmacokinetics and Safety of Voriconazole following Intravenous- to Oral-Dose Escalation Regimens , 2002, Antimicrobial Agents and Chemotherapy.

[20]  H. Derendorf,et al.  Pharmacokinetic/Pharmacodynamic Profile of Voriconazole , 2006, Clinical pharmacokinetics.

[21]  D. Flockhart,et al.  Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.